Figure 2 | Blood Cancer Journal

Figure 2

From: Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome

Figure 2

Peripheral mononuclear cell histone acetylation changes as assessed by mean fluorescent intensity (MFI) change in (a) histone H3 and (b) histone H4 during cycle 1 of therapy, or (c) according to panobinostat dose on day 19 relative to baseline for histone H4. (d) Patients with 50% or greater increases in histone H4 acetylation on day 19 relative to day 5 had a higher frequency of clinical response than did patients with lesser degrees of acetylation. **=P<0.01. (e) Dynamic changes in GADD45A CpG1 methylation during cycle 1 in patients with dominant circulating peripheral blood blasts. (f) Mean+s.d of Nur77 gene expression levels in peripheral blood mononuclear cells during cycle 1.

Back to article page